Zhejiang Medicine Subsidiary Passes US FDA Inspection for Antibiotic

MT Newswires Live

02-27

Zhejiang Medicine (SHA:600216) subsidiary Innovative Biotechnology passed the US Food and Drug Administration's current good manufacturing practice inspection for its production line for vancomycin hydrochloride for injection.

The inspection was conducted from Oct. 30 to Nov. 8, 2024, according to a Thursday filing with the Shanghai bourse.

Vancomycin is suitable for infections caused by methicillin-resistant staphylococcus aureus and other bacteria.

Shares of the drug company closed 2% higher Thursday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2514582033"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2514582033\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2514582033?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-02-27 16:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2514582033","market":"sh","top_or_hot":-1,"title":"Zhejiang Medicine Subsidiary Passes US FDA Inspection for Antibiotic","media":"MT Newswires Live","content":"<html><body><p> Zhejiang Medicine (SHA:600216) subsidiary Innovative Biotechnology passed the US Food and Drug Administration's current good manufacturing practice inspection for its production line for vancomycin hydrochloride for injection.</p><p>The inspection was conducted from Oct. 30 to Nov. 8, 2024, according to a Thursday filing with the Shanghai bourse.</p><p>Vancomycin is suitable for infections caused by methicillin-resistant staphylococcus aureus and other bacteria.</p><p>Shares of the drug company closed 2% higher Thursday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Zhejiang Medicine Subsidiary Passes US FDA Inspection for Antibiotic</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nZhejiang Medicine Subsidiary Passes US FDA Inspection for Antibiotic\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-02-27 16:58</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Zhejiang Medicine (SHA:600216) subsidiary Innovative Biotechnology passed the US Food and Drug Administration's current good manufacturing practice inspection for its production line for vancomycin hydrochloride for injection.</p><p>The inspection was conducted from Oct. 30 to Nov. 8, 2024, according to a Thursday filing with the Shanghai bourse.</p><p>Vancomycin is suitable for infections caused by methicillin-resistant staphylococcus aureus and other bacteria.</p><p>Shares of the drug company closed 2% higher Thursday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK0191","symbol_name":"維生素","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2514582033","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2514582033","pubTimestamp":1740646703,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zhejiang Medicine  subsidiary Innovative Biotechnology passed the US Food and Drug Administration's current good manufacturing practice inspection for its production line for vancomycin hydrochloride for injection.The inspection was conducted from Oct. 30 to Nov. 8, 2024, according to a Thursday filing with the Shanghai bourse.Vancomycin is suitable for infections caused by methicillin-resistant staphylococcus aureus and other bacteria.Shares of the drug company closed 2% higher Thursday.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600216":"浙江医药","BK0191":"维生素","BK0188":"融资融券","BK0028":"国家队","BK0239":"医药制造"},"translate_title":"浙江医药子公司抗生素通过美国FDA检查","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600216":0.9},"content_text":"Zhejiang Medicine (SHA:600216) subsidiary Innovative Biotechnology passed the US Food and Drug Administration's current good manufacturing practice inspection for its production line for vancomycin hydrochloride for injection.The inspection was conducted from Oct. 30 to Nov. 8, 2024, according to a Thursday filing with the Shanghai bourse.Vancomycin is suitable for infections caused by methicillin-resistant staphylococcus aureus and other bacteria.Shares of the drug company closed 2% higher Thursday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"code":"91000000","status":"200"}}}